

Guangjun Shi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5710456/publications.pdf>

Version: 2024-02-01

16
papers

316
citations

1040056

9
h-index

1058476

14
g-index

17
all docs

17
docs citations

17
times ranked

439
citing authors

#	ARTICLE	IF	CITATIONS
1	A Circular RNA, Cholangiocarcinoma-Associated Circular RNA 1, Contributes to Cholangiocarcinoma Progression, Induces Angiogenesis, and Disrupts Vascular Endothelial Barriers. <i>Hepatology</i> , 2021, 73, 1419-1435.	7.3	103
2	Irisin stimulates cell proliferation and invasion by targeting the PI3K/AKT pathway in human hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2017, 493, 585-591.	2.1	65
3	<p>Review of Research on the Role of Irisin in Tumors</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 4423-4430.	2.0	29
4	<p>Irisin functions to inhibit malignant growth of human pancreatic cancer cells via downregulation of the PI3K/AKT signaling pathway</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7243-7249.	2.0	21
5	FND5 induces M2 macrophage polarization and promotes hepatocellular carcinoma cell growth by affecting the PPAR γ /NF- κ B/NLRP3 pathway. <i>Biochemical and Biophysical Research Communications</i> , 2021, 582, 77-85.	2.1	21
6	Panx1 promotes invasion-metastasis cascade in hepatocellular carcinoma. <i>Journal of Cancer</i> , 2019, 10, 5681-5688.	2.5	15
7	FND5 Causes Resistance to Sorafenib by Activating the PI3K/Akt/Nrf2 Pathway in Hepatocellular Carcinoma Cells. <i>Frontiers in Oncology</i> , 2022, 12, 852095.	2.8	14
8	Enhanced expression of ten β eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P α glycoprotein expression. <i>Cancer Medicine</i> , 2019, 8, 990-1003.	2.8	13
9	Circ_ASPH promotes cholangiocarcinoma growth and metastasis through the miR α 581/ATP β binding cassette transporter G1 signaling pathway. <i>Cancer Communications</i> , 2020, 40, 545-550.	9.2	9
10	Tanshinone IIA affects the malignant growth of Cholangiocarcinoma cells by inhibiting the PI3K-Akt-mTOR pathway. <i>Scientific Reports</i> , 2021, 11, 19268.	3.3	7
11	Survival outcomes of combined hepatocellular α cholangiocarcinoma compared with intrahepatic cholangiocarcinoma: A SEER population β based cohort study. <i>Cancer Medicine</i> , 2022, 11, 692-704.	2.8	5
12	Development and Validation of Nomograms to Predict Overall Survival and Cancer-Specific Survival in Patients With Pancreatic Adenosquamous Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 831649.	2.8	5
13	Comprehensive Analysis of HOX Family Members as Novel Diagnostic and Prognostic Markers for Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-17.	1.3	4
14	Bone marrow mesenchymal stem cells inhibit cardiac hypertrophy by enhancing FoxO1 transcription. <i>Cell Biology International</i> , 2021, 45, 188-197.	3.0	3
15	Comprehensive analysis of immune-related prognostic genes in the tumour microenvironment of hepatocellular carcinoma. <i>BMC Cancer</i> , 2021, 21, 331.	2.6	1
16	A Panel of E2F Target Gene Signature Predicting the Prognosis of Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 879299.	2.3	1